Lun - Ven 8:00 - 17:00
The assessment included an online slide presentation followed by a comprehension test that proved the medical professionals knew and understood the drug’s risks of potential low blood pressure and fainting when combined with alcohol. Even further, patients had to sign a paper vowing not to drink while on the medication even though Cialis--another medication used to treat erectile dysfunction in men--creates similar interactions with alcohol but comes with no more than an advisement to moderate alcohol use.
At the time of approval, the FDA argued that Addyi’s interaction with alcohol hadn’t yet been adequately studied. In 2019 and after additional research was conducted, the FDA modified its original alcohol warning for Addyi and removed the test requirement for doctors and pharmacists. In December of 2025, the FDA approved the drug for postmenopausal women, expanding access to more patients. Advocates say a drug to treat women’s sexual dysfunction is a start to addressing health inequity. Lee adds that recent bigger picture events, though, like the overturn of Roe v.
Do not take Addyi if you have liver problems. Using Addyi In patients with liver impairment may lead to severe low blood pressure and fainting. Addyi should not be used in these settings. Ask your doctor or pharmacist if you are not sure if you have liver disease. Dizziness, tiredness, and nausea in about 10% to 11% of patients (vs.
2% to 4% receiving a placebo). Addyi can increase the risk of sleepiness if taken during waking hours. Fatigue, trouble sleeping and dry mouth have also been reported. The risk of severe low blood pressure and fainting may occur when Addyi is used alone or when combined with alcohol or certain other medicines or herbal supplements. Do not drink alcohol close to the time you take your Addyi dose because this increases your risk of severe low blood pressure and fainting (loss of consciousness). Wade and rollbacks on birth control access, have changed what health care looks like for women today. The approval and acceptance of Addyi is part of a much larger and ongoing conversation about women’s health and regulatory policy currently. “The viagra vardenafil 20mg past five to 10 years really calls into question where the state of women’s health is going,” Lee said.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 200mg | 20 Pills | 61.69€ 58.75€ | |
| Viagra Professional | 100mg | 20 Pills | 71.14€ 67.75€ | |
| Viagra Soft Tabs | 100mg | 120 + 8 Pills | 232.21€ 221.15€ | |
| Viagra Super Active | 100mg | 270 + 30 Pills | 390.61€ 372.01€ | |
| Viagra Oral Jelly | 100mg | 110 + 9 Sachets | 284.63€ 271.08€ | |
| Viagra Generic | 25mg | 270 + 8 Pills | 184.26€ 175.49€ | |
| Viagra Professional | 100mg | 120 + 4 Pills | 262.83€ 250.31€ | |
| Viagra Soft Tabs | 100mg | 90 + 6 Pills | 205.31€ 195.53€ | |
| Viagra Super Active | 100mg | 120 + 16 Pills | 198.37€ 188.92€ | |
| Viagra Generic | 200mg | 120 + 8 Pills | 204.80€ 195.05€ | |
| Viagra Super Active | 100mg | 90 + 10 Pills | 165.61€ 157.72€ | |
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ | |
| Viagra Original | 100mg | 48 + 4 Pills | 207.15€ 197.29€ |
The Pink Pill: Sex, Drugs & Who Has Control is streaming on Paramount+ in Canada and the U.S.
| Risk | Explanation | Recommendations |
|---|---|---|
| Heart Problems | Can stress cardiovascular system | Consult doctor if cardiac issues |
| Drug Interactions | Interacts with nitrates, certain antihypertensives | Avoid concurrent use |
| Overdose | Can cause severe hypotension, priapism | Follow prescribed dosage |
| Allergic Reactions | Rash, swelling, difficulty breathing | Seek medical help immediately |
| Age Restrictions | Not recommended for under 18 | Use only as prescribed |
as of March 6, 2026.
Given the success of medicines to treat trouble getting and keeping an erection, called erectile dysfunction, companies have looked for a medicine to help women with sex.
| Country | Regulatory Status | Notes |
|---|---|---|
| USA | Approved generics available | OTC and prescription options available |
| UK | Prescription required | Strict regulation |
| Australia | Approved for medical use | Import restrictions apply |
| India | Widely manufactured, some unregulated brands | Varies in quality |
| Canada | Prescription only | Clinical evaluation necessary |
Viagra even has been tried as a treatment for sexual dysfunction in women.
But the U.S. Food and Drug Administration (FDA) hasn't approved this use of Viagra. For years there were no FDA-approved medicines for treating problems with sexual arousal or sexual desire in women. Yet 4 in 10 women report having sexual concerns.
If you take Addyi and feel dizzy or lightheaded, lie down right away if you feel like you could faint. Get emergency help or ask someone else to do this. If you faint, tell your doctor as soon as possible. Do not drive, operate machinery, or do things that require clear thinking until at least 6 hours after you take Addyi and until you know how this medicine affects you. You can learn more about Addyi side effects here.
This is not all the information you need to know about Addyi (flibanserin) for safe and effective use and does not take the place of your doctor’s directions. Review the full product and patient information and discuss this information and any questions you have with your doctor or other health care provider. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis. Simon JA, Thorp J, Millheiser L. The FDA now has approved two medicines.
alone there are nearly a million patients taking oral medication to treat their autoimmune condition. Though HSDD is not a threat to physical wellbeing, both conditions can have significant impact on a person’s life. Like most medications, Addyi doesn’t work for everyone, but its availability gives women struggling with HSDD an option that otherwise doesn’t exist. Still, early research didn’t quite satisfy the FDA. “When the data first went up for review in 2010, the FDA did not feel that there was enough data to support Addyi’s effectiveness,” said Lee.
The drug was originally tested in a clinical trial with over 2,000 premenopausal women either taking Addyi or a placebo pill. Participants taking Addyi were 10% more likely to report an increase in satisfying sexual events. A more recent study found that about half of women taking Addyi reported benefit to their sex life. Advocates for women’s health criticized the FDA’s early rejections and claimed gender bias, especially because Viagra was approved under an expedited priority review process, taking less than a year to achieve approval. Though the purposes of Addyi and Viagra are similar, Addyi corrects chemical imbalances of certain neurotransmitters in the brain that are responsible for sexual desire or excitement, which makes the drug approval process more complex. The FDA has approved a daily pill called flibanserin (Addyi) to treat low sexual desire in women before menopause. This medicine started as a treatment for depression. Addyi may boost sex drive in women with low sexual desire. It's for women who are not happy with their low sex drive. Possible serious side effects include low blood pressure, dizziness and fainting.
“When you look at women — premenopausal, postmenopausal, transgender individuals — the conversation of what is available to you is not dictated by you,” explains Johns Hopkins Carey Business School Law and Ethics Professor Stacey Lee in The Pink Pill: Sex, Drugs & Who Has Control. Addyi, or flibanserin, treats Hypoactive Sexual Desire Disorder, a common condition defined by lack of sexual desire in women. It has yet to achieve the same kind of widespread use or acceptance as men’s Viagra, which is used by millions of patients annually since its 1998 debut. The Pink Pill recounts the journey of Sprout Pharmaceuticals Founder and CEO Cindy Eckert, the entrepreneur whose company developed and brought Addyi to market, as she set out to expand access for sexual health treatments for women. Eckert’s path in developing Addyi for patient use was more of a struggle than it should’ve been, according to the documentary, which calls out the inequalities in availability of sexual health treatment between men and women.
Lee highlights that FDA choices and approvals are not just regulatory decisions, but that they also shape who can get care and how easily. “If you’re a cisgender, white male, health care in the United States is pretty darn good, and your health care experience can be a uniquely personal one,” she said. In other words, women and minority groups often don’t have a similar, positive experience. “FDA decisions are not just scientific determinations, but structural choices that shape access, risk, and who benefits from innovation,” said Lee. The FDA declined approval for Addyi in 2010 and 2013, with some critics referring to the treatment as “an ineffective drug for a nonexistent problem.” However, data from the University of Colorado Anschutz Department of Obstetrics and Gynecology shows that 10% of women across all age groups suffer from HSDD, which can “cause significant levels of personal distress.” To put it into perspective, HSDD is just as common as autoimmune disorders like rheumatoid arthritis, and in the U.S. These side effects are more likely to happen if the medicine is mixed with alcohol.
“Erectile dysfunction was seen as an unmet physical ailment,” said Lee. Because of that, Viagra was evaluated as treatment to address a physical need. HSDD was not considered an unmet physical ailment in the eyes of the FDA but rather an unmet psychological ailment, which “immediately triggers a higher standard of review and additional safety measures,” Lee adds. While the drugs had to be evaluated differently, supporters of Addyi claimed that stigma and overly cautious FDA warnings deterred patient use even after it was approved. For example, doctors and pharmacists had to take a test, known as a Risk Evaluation and Mitigation Strategy assessment, to prescribe and administer Addyi. The FDA says not to drink alcohol if you take this medicine. Experts suggest that you stop taking the medicine if your sex drive doesn't improve after eight weeks.
Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials. 2019 Jun;28(6):769-777. doi: 10.1089/jwh.2018.7516 Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. Joint Meeting of the Bone, viagra gel Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee.
How does Addyi work and is it effective? Vyleesi vs Addyi: What is the difference? Can I take Addyi while drinking alcohol? Hypoactive Sexual Desire Disorder (4 questions, 28 members) While sexual dysfunction affects both men and women, men have 26 FDA-approved treatments to choose from. A new documentary explains that it’s in part because the FDA drug approval process determines which sexual health options are available, and how restrictions or labeling decisions can limit access for certain groups. The FDA also has approved a medicine given as a shot to treat low sexual desire in women before menopause.
Bremelanotide (Vyleesi) is injected under the skin in the belly or thigh at least 45 minutes before having sex. It should not be used more than once a day or more than eight times a month.
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités